Log in

TG Therapeutics (NASDAQ:TGTX) Upgraded to "Buy" at ValuEngine

Last updated on Monday, August 3, 2020 | 2020 MarketBeat

TG Therapeutics (NASDAQ:TGTX) was upgraded by equities researchers at ValuEngine from a "hold" rating to a "buy" rating in a research report issued on Monday, ValuEngine reports.

TGTX has been the subject of a number of other reports. Evercore ISI started coverage on TG Therapeutics in a research note on Friday, June 5th. They issued an "outperform" rating and a $60.00 target price for the company. HC Wainwright reissued a "buy" rating on shares of TG Therapeutics in a research note on Friday, May 29th. BidaskClub cut TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday. Zacks Investment Research cut TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Cantor Fitzgerald boosted their target price on TG Therapeutics from $19.00 to $35.00 and gave the company an "overweight" rating in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of "Buy" and a consensus target price of $38.00.

Shares of TG Therapeutics stock traded up $1.23 during trading on Monday, reaching $20.81. 1,551,916 shares of the company were exchanged, compared to its average volume of 2,114,571. The company has a quick ratio of 1.39, a current ratio of 1.39 and a debt-to-equity ratio of 1.01. TG Therapeutics has a twelve month low of $4.95 and a twelve month high of $24.76. The business has a 50-day moving average price of $20.56 and a 200-day moving average price of $15.70. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.25 and a beta of 2.41.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.12). TG Therapeutics had a negative net margin of 124,230.27% and a negative return on equity of 2,937.74%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. On average, equities research analysts forecast that TG Therapeutics will post -1.38 EPS for the current fiscal year.

In other news, Director William James Kennedy sold 7,745 shares of the business's stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $18.27, for a total value of $141,501.15. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 13.20% of the company's stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. Bank of New York Mellon Corp raised its holdings in TG Therapeutics by 4.8% during the fourth quarter. Bank of New York Mellon Corp now owns 324,590 shares of the biopharmaceutical company's stock worth $3,602,000 after acquiring an additional 14,901 shares in the last quarter. AQR Capital Management LLC bought a new stake in TG Therapeutics during the fourth quarter worth about $401,000. Ladenburg Thalmann Financial Services Inc. raised its holdings in TG Therapeutics by 47.4% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,327 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 3,000 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in TG Therapeutics by 5.2% during the fourth quarter. Nuveen Asset Management LLC now owns 313,458 shares of the biopharmaceutical company's stock worth $3,479,000 after acquiring an additional 15,450 shares in the last quarter. Finally, Redhawk Wealth Advisors Inc. bought a new stake in TG Therapeutics during the first quarter worth about $98,000. Institutional investors and hedge funds own 58.82% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Read More: Example of operating income, EBIT and EBITDA

To view ValuEngine's full report, visit ValuEngine's official website.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

8 Retail Stocks to Own For the Long Haul

There are more than 500 national retailers traded on the NYSE and the NASDAQ. Given the sheer number of big box stores, warehouse clubs, restaurant chains and other retail stores listed on public markets, it can be hard to identify which retailers are going to outperform the market.

Fortunately, some of Wall Street's top analysts have already done most of the work for us.

Every year, analyst issue approximately 4,200 distinct recommendations for retail companies. Analysts may not always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same retailer.

This slide show lists the 8 retail companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

View the "8 Retail Stocks to Own For the Long Haul".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.